Outlook Therapeutics Inc

Research Outlook Therapeutics Inc (41ON) with Bullrun company financials, valuation charts, model signals, and historical stock context.

Key Metrics

• Ticker41ON
• ExchangeSTU
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR

About Outlook Therapeutics Inc

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc.

Frequently asked questions

What does Outlook Therapeutics Inc do?

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications.